Literature DB >> 22322297

STAT3-mediated signaling dysregulates lung fibroblast-myofibroblast activation and differentiation in UIP/IPF.

Dmitri V Pechkovsky1, Cecilia M Prêle, John Wong, Cory M Hogaboam, Robin J McAnulty, Geoffrey J Laurent, Samuel S-M Zhang, Moisés Selman, Steven E Mutsaers, Darryl A Knight.   

Abstract

STAT3 is a latent transcription factor that plays a role in regulating fibroblast function in fibrotic lung diseases. To further understand the role of STAT3 in the phenotypic divergence and function of human lung fibroblasts (LFs), we investigated the effect of basal and cytokine-induced STAT3 activity on indices of LF differentiation and activation, including expression of α-smooth muscle actin (α-SMA), collagen, and adhesion molecules Thy-1/CD90 and α(v) β(3) and β(5) integrins. We identified a population of fibroblasts from usual interstitial pneumonia (UIP)/idiopathic pulmonary fibrosis (IPF) lungs characterized by constitutively phosphorylated STAT3, lower proliferation rates, and diminished expression of α-SMA, Thy-1/CD90, and β(3) integrins compared with control LFs. Staining of UIP lung biopsy specimens demonstrated that phosphorylated STAT3 was not present in α-SMA-positive fibroblastic foci but was observed in the nuclei of cells located in the areas of dense fibrosis. STAT3 activation in LFs did not significantly influence basal or transforming growth factor β(1)-induced collagen I expression but inhibited expression of α-SMA, Thy-1/CD90, and αv β(3) integrins. Suppression of STAT3 signaling diminished resistance of IPF LFs to staurosporine-induced apoptosis and responsiveness to transforming growth factor β(1) but increased basal α-SMA and restored β(3) integrin expression in LFs via an ALK-5-dependent, SMAD3/7-independent mechanism. These data suggest that STAT3 activation regulates several pathways in human LFs associated with normal wound healing, whereas aberrant STAT3 signaling plays a critical role in UIP/IPF pathogenesis.
Copyright © 2012 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22322297     DOI: 10.1016/j.ajpath.2011.12.022

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  45 in total

1.  Altered DNA methylation profile in idiopathic pulmonary fibrosis.

Authors:  Yan Y Sanders; Namasivayam Ambalavanan; Brian Halloran; Xiangyu Zhang; Hui Liu; David K Crossman; Molly Bray; Kui Zhang; Victor J Thannickal; James S Hagood
Journal:  Am J Respir Crit Care Med       Date:  2012-06-14       Impact factor: 21.405

2.  Enhanced neointimal fibroblast, myofibroblast content and altered extracellular matrix composition: Implications in the progression of human peripheral artery restenosis.

Authors:  Prakash Krishnan; K-Raman Purushothaman; Meerarani Purushothaman; Irene C Turnbull; Arthur Tarricone; Miguel Vasquez; Sachin Jain; Usman Baber; Rheoneil A Lascano; Annapoorna S Kini; Samin K Sharma; Pedro R Moreno
Journal:  Atherosclerosis       Date:  2016-06-30       Impact factor: 5.162

3.  Emerging therapies for idiopathic pulmonary fibrosis, a progressive age-related disease.

Authors:  Ana L Mora; Mauricio Rojas; Annie Pardo; Moises Selman
Journal:  Nat Rev Drug Discov       Date:  2017-10-30       Impact factor: 84.694

4.  Plasminogen activator inhibitor-1 suppresses profibrotic responses in fibroblasts from fibrotic lungs.

Authors:  Amarnath S Marudamuthu; Shwetha K Shetty; Yashodhar P Bhandary; Sophia Karandashova; Michael Thompson; Venkatachalem Sathish; Galina Florova; Taryn B Hogan; Christina M Pabelick; Y S Prakash; Yoshikazu Tsukasaki; Jian Fu; Mitsuo Ikebe; Steven Idell; Sreerama Shetty
Journal:  J Biol Chem       Date:  2015-02-03       Impact factor: 5.157

Review 5.  Targeting oncogenic ALK and MET: a promising therapeutic strategy for glioblastoma.

Authors:  Gerald C Wallace; Yaenette N Dixon-Mah; W Alex Vandergrift; Swapan K Ray; Catherine P Haar; Amber M Mittendorf; Sunil J Patel; Naren L Banik; Pierre Giglio; Arabinda Das
Journal:  Metab Brain Dis       Date:  2013-04-02       Impact factor: 3.584

6.  Wilms' tumor 1 drives fibroproliferation and myofibroblast transformation in severe fibrotic lung disease.

Authors:  Vishwaraj Sontake; Rajesh K Kasam; Debora Sinner; Thomas R Korfhagen; Geereddy B Reddy; Eric S White; Anil G Jegga; Satish K Madala
Journal:  JCI Insight       Date:  2018-08-23

7.  Interleukin-6-mediated trans-signaling inhibits transforming growth factor-β signaling in trabecular meshwork cells.

Authors:  Miyuki Inoue-Mochita; Toshihiro Inoue; Sachi Kojima; Akiko Futakuchi; Tomokazu Fujimoto; Saori Sato-Ohira; Utako Tsutsumi; Hidenobu Tanihara
Journal:  J Biol Chem       Date:  2018-05-11       Impact factor: 5.157

8.  Oncostatin M overexpression induces matrix deposition, STAT3 activation, and SMAD1 Dysregulation in lungs of fibrosis-resistant BALB/c mice.

Authors:  Steven Wong; Fernando M Botelho; Rebecca M Rodrigues; Carl D Richards
Journal:  Lab Invest       Date:  2014-06-16       Impact factor: 5.662

Review 9.  Cell Receptor-Basement Membrane Interactions in Health and Disease: A Kidney-Centric View.

Authors:  Corina M Borza; Xiwu Chen; Roy Zent; Ambra Pozzi
Journal:  Curr Top Membr       Date:  2015       Impact factor: 3.049

10.  STAT-3 contributes to pulmonary fibrosis through epithelial injury and fibroblast-myofibroblast differentiation.

Authors:  Mesias Pedroza; Thuy T Le; Katherine Lewis; Harry Karmouty-Quintana; Sarah To; Anuh T George; Michael R Blackburn; David J Tweardy; Sandeep K Agarwal
Journal:  FASEB J       Date:  2015-08-31       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.